Saltar al contenido
Merck
  • Myocardin-related transcription factors control the motility of epicardium-derived cells and the maturation of coronary vessels.

Myocardin-related transcription factors control the motility of epicardium-derived cells and the maturation of coronary vessels.

Development (Cambridge, England) (2014-12-18)
Michael A Trembley, Lissette S Velasquez, Karen L de Mesy Bentley, Eric M Small
RESUMEN

An important pool of cardiovascular progenitor cells arises from the epicardium, a single layer of mesothelium lining the heart. Epicardium-derived progenitor cell (EPDC) formation requires epithelial-to-mesenchymal transition (EMT) and the subsequent migration of these cells into the sub-epicardial space. Although some of the physiological signals that promote EMT are understood, the functional mediators of EPDC motility and differentiation are not known. Here, we identify a novel regulatory mechanism of EPDC mobilization. Myocardin-related transcription factor (MRTF)-A and MRTF-B (MKL1 and MKL2, respectively) are enriched in the perinuclear space of epicardial cells during development. Transforming growth factor (TGF)-β signaling and disassembly of cell contacts leads to nuclear accumulation of MRTFs and the activation of the motile gene expression program. Conditional ablation of Mrtfa and Mrtfb specifically in the epicardium disrupts cell migration and leads to sub-epicardial hemorrhage, partially stemming from the depletion of coronary pericytes. Using lineage-tracing analyses, we demonstrate that sub-epicardial pericytes arise from EPDCs in a process that requires the MRTF-dependent motile gene expression program. These findings provide novel mechanisms linking EPDC motility and differentiation, shed light on the transcriptional control of coronary microvascular maturation and suggest novel therapeutic strategies to manipulate epicardium-derived progenitor cells for cardiac repair.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
ANTI-FLAG® M2 monoclonal antibody produced in mouse, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)
Sigma-Aldrich
4-hidroxitamoxifeno, ≥70% Z isomer (remainder primarily E-isomer)
Sigma-Aldrich
Anti-actina, α-músculo liso monoclonal, clone 1A4, ascites fluid
Sigma-Aldrich
Luminol, 97%
Sigma-Aldrich
Anticuerpo anti-gliceraldehído-3-fosfato deshidrogenasa, clon 6C5, clone 6C5, Chemicon®, from mouse
Sigma-Aldrich
Deoxycholic acid, ≥98% (HPLC)
Sigma-Aldrich
Luminol, ≥97% (HPLC)
Sigma-Aldrich
Deoxycholic acid, ≥99.0% (T)
Supelco
4-hidroxitamoxifeno, analytical standard, (E) and (Z) isomers (50:50)
Supelco
4-hidroxitamoxifeno, (E) and (Z) isomers (50:50), analytical standard